CEVA Enters Parasiticide Market With Summit VetPharm Purchase

Veterinary pharmaceutical group CEVA of France reported today that it is entering the flea and tick control market by acquiring a majority share of Sumitomo Corp.’s animal health subsidiary Summit VetPharm LLC.

Veterinary pharmaceutical group CEVA of France reported today that it is entering the flea and tick control market by acquiring a majority share of Sumitomo Corp.’s animal health subsidiary Summit VetPharm LLC.

Sumitomo will remain a minority shareholder in the new North American CEVA companion animal business, which will include the assets of Summit VetPharm.

Summit VetPharm’s products include Vectra 3D, Vectra for Cats & Kittens, Vectra for Cats and Vectra for Dogs & Puppies, which are available exclusively through veterinarians. The Rutherford, N.J., company also incorporates Bloodhound Technology, which traces product packages from the site of manufacture to veterinary purchase to help ensure veterinary exclusivity and product authenticity.

“Summit VetPharm is an excellent business, led by a management team that shares our own entrepreneurial business approach,” said Marc Prikazsky, chairman and CEO of CEVA. “Geographically, it’s a perfect fit, giving CEVA a strengthened position in the U.S. companion animal health market.

"Vectra is a signature brand which has achieved impressive market share since its launch in the United States and can be developed throughout our global network to benefit companion animals worldwide.”

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *